ETF (UCITS compliant)

L&G Healthcare Breakthrough UCITS ETF

Fund facts

Fund size*
$219.8m
Base currency
USD
Listing date
2 Jul 2019
Domicile
Ireland
Index ticker
HTECTR
Replication method
Physical - full replication

Statistics

*As at 22 Oct 2021

Fund aim

The L&G Healthcare Breakthrough UCITS ETF (the "ETF") aims to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”).

  • Long-term allocation

Long-term megatrend that we believe is radically transforming the way we live and work

  • High growth potential

Aims to capture the outsized growth potential of the healthcare technology industry

  • Leveraging industry expertise

An index tracking investment strategy that is supported by a team of healthcare technology experts

  • Does it have a sustainable objective?

The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.

ROBO Global® Healthcare Technology and Innovation Index TR

The Index aims to track the performance of a basket of companies that are actively engaged in the healthcare technology value-chain.

The index is comprised of companies which are publicly traded on various stock exchanges around the world that have a distinct portion of their business and revenue derived from the field of healthcare technologies, and the potential to grow within this space through innovation and/or market adoption of their products and/or services. Companies are included in the index receive a "HTEC Score"  comprised of factors representing (1)the levels of revenue the company receives from innovative healthcare technologies, (2) the levels of investment the firm makes in healthcare technologies, (3) the market and technology leadership of the firm within the universe.

A company is only eligible for inclusion in the Index if it is of a sufficient size (determined by reference to the total market value of its shares) and it is sufficiently "liquid" ( a measure of how actively its shares are traded on a daily basis). Within the Index, companies are weighted according a modified HTEC-factor weighting scheme. The Index is rebalanced quarterly in March, June, September and December.

Index data

Provider
ROBO Global®
Bloomberg code
HTECTR
Reuters code
.HTECTR
Type
Total Return
Website
https://www.roboglobal.com/robo-global-indices/htec-index/

Performance

Source: Lipper.

Performance (%)
Select period:
Change

    Performance summary (%)

    As at 30 Sep 2021

    CumulativeFundBenchmark
    1 month-6.56-6.72
    6 months3.943.97
    Year to date4.394.53
    3 years--
    5 years--
    Since launch89.3491.06
    AnnualisedFundBenchmark
    1 year30.7831.12
    3 years--
    5 years--
    Since launch32.5033.03

    As at 30 Sep 2021

    CumulativeFundBenchmark
    Quarterly-5.19-5.28
    Year to date4.394.53
    3 years--
    5 years--
    Since launch89.3491.06
    AnnualisedFundBenchmark
    1 year30.7831.12
    3 years--
    5 years--
    Since launch32.5033.03
    Rolling 12-month performance
    Calendar year performance
    Monthly performance
    Annualised performance

    Rolling 12-month performance to last quarter end (%)

    12 months to 30 September 2017 2018 2019 2020 2021
    Fund---49.2430.78
    Benchmark---50.0531.12

    Calendar year performance (%)

    2016 2017 2018 2019 2020
    Fund----65.72
    Benchmark----66.55

    Monthly performance (%)

    Annualised performance (%)

    1 year3 years5 yearsSince launch
    Fund30.78--32.50
    Benchmark31.12--33.03

    Annualised performance (%)

    1 year3 years5 yearsSince launch
    Fund30.78--32.50
    Benchmark31.12--33.03

    Performance for the USD Accumulating ETF class in USD, listed on 02 July 2019. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.

    Past performance is not a guide to the future.

    Portfolio

    As at 30 Sep 2021. All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding.

    The breakdowns below relate to the Index. The ETF’s portfolio may deviate from the below

    Sector (%)

    Medical Instruments26.2
    Diagnostics14.8
    Precision Medicine12.9
    Process Automation12.7
    Genomics11.0
    Telehealth6.8
    Data Analytics6.7
    Robotics5.6
    Regenerative Medicine3.4

    Currency (%)

    USD82.2
    EUR6.1
    CHF3.6
    HKD3.5
    GBP1.8
    AUD1.1
    JPY0.8
    DKK0.8
    Top 10 constituents15.1
    Rest of Index84.9
    No. of constituents in Index87

    Top 10 constituents (%)

    Irhythm Technologies1.9
    Dexcom1.6
    Thermo Fisher Scientific1.6
    Boston Scientific1.5
    Insulet1.5
    Intuitive Surgical1.4
    Penumbra1.4
    Charles River Laboratories1.4
    Axogen1.4
    Integra Lifesciences1.4

    Country (%)

    United States80.7
    Switzerland3.6
    Cayman Islands2.5
    United Kingdom1.8
    Germany1.4
    Italy1.3
    Netherlands1.2
    Australia1.1
    Spain1.1
    Other5.4

    Sustainability

    Sustainability disclosures

    The Sustainable Finance Disclosure Regulation (SFDR) is an EU regulation that came into force on 10 March 2021, and imposes disclosure requirements for EU financial products. These requirements include disclosing sustainability-related information for funds that (i) promote (among other characteristics) environmental or social characteristics (Article 8 products), or (ii) have a sustainable investment objective (Article 9 products), both as defined under SFDR.

    SFDR categorisation: Article 9Article 9: These funds have a sustainable investment objective

    The Fund has a sustainable investment objective. The Fund invests in companies which (i) contribute to a social objective, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. The Fund seeks to achieve its sustainable objective by tracking an index (the "Index") which seeks to provide exposure to companies which are actively engaged in the healthcare technology value-chain which seek to contribute to increased efficiency and effectiveness in healthcare and promote advancements and innovation in the healthcare industry.

    The Index Provider seeks to ensure that only companies which are actively engaged in the healthcare technology value-chain which seek to contribute to increased efficiency and effectiveness in healthcare and promote advancements and innovation in the healthcare industry are selected in accordance with the ROBO Global® Industry Classification methodology and included in the Index. The Index includes companies which derive a proportion of their revenues from the following sub-sectors of the field of healthcare innovation and technology:

    • Diagnostic;
    • Lab Process Automation;
    • Genomics;
    • Regenerative Medicine;
    • Precision Medicine;
    • Telehealth;
    • Data Analytics;
    • Robotics; and
    • Medical Instruments.

    The Index Provider may exclude companies from the ROBO Global® Industry Classification if a company fails to adhere to ROBO Global’s ESG policy, including companies where there is an unacceptable risk that the company contributes to or is responsible for serious human rights violations, severe environmental damage, and other particularly serious violations of fundamental ethical norms, including the production of weapons that violate fundamental humanitarian principles through their normal use. Additionally, the Index Provider aims to ensure that companies in the Index have no direct exposure to fossil fuels. As part of the Index Provider’s ESG evaluation, a company’s alignment with the 10 principles of the UN Global Compact, including human rights, labour rights, environmental impacts, and business ethics are considered. The Index Provider evaluates ESG factors using a combination of internal research, regular interaction with index member companies, as well as support from leading ESG research providers to ensure they comply with all aspects of the ROBO Global ESG Policy.

    Stock selection
    Carbon intensity
    Future World Protection List
    Climate Impact Pledge
    Exclusions
    Tilting
    Paris-aligned benchmark optimisation
    ESG integration

    Having assessed the existing constituents of the Index, we have concluded that such investments do not significantly harm any environmental and social objectives. We have implemented processes and checks, using both environmental and social indicators, to verify on a bi-annual basis that the Fund’s investments do not cause any significant harm to any such objectives.

    The data used to construct the index is sourced from independent third party data providers.

    The Index Provider, ROBO Global® LLC, determines the constituents of the Index.

    Further information on the index methodology can be found at: https://www.roboglobal.com/robo-global-indices/htec-index/

    The above information in respect of the Index has been derived by us from methodologies, statements and disclosures of the index provider for purposes of satisfying our disclosure requirements under SFDR. The information is, therefore, not the property of LGIM and is provided “as is” and “as available”. We seek to ensure the information in respect of the Index is up to date, however there is no guarantee or representations made as to the accuracy or completeness of the information at all times. On that basis, and to the maximum extent permitted by law, no liability is accepted by us in respect of this information.

    A description of the extent to which the environmental and social characteristics are met will likely be made available as part of the annual report published in 2022 as required by SFDR. The Fund’s most recent annual report does not include any information pursuant to SFDR.

    Pre-contractual disclosure

    The Fund has a sustainable objective as it invests in companies which (i) contribute to a social objective, (ii) do not significantly harm any environmental or social objectives and its investee companies follow good governance practices. The investment objective of the Fund is to provide exposure to the global healthcare technology industry. The Fund is passively managed and pursues its investment objective by seeking to track the performance of the Index. The Index differs from a broad market index as it seeks to provide exposure to companies which are actively engaged in the healthcare technology value-chain which seek to contribute to increased efficiency and effectiveness in healthcare and promote advancements and innovation in the healthcare industry. Further information on the Index can be found in the “Index Description” section below, and at http://www.roboglobal.com/eu-index.

    The Manager aims to ensure that the issuers of investments in which the Fund is invested follow good governance practices. This is achieved by 1) setting expectations with the issuers’ management with regard to good governance practices; 2) active engagement with the issuers; 3) utilising its voting rights; and 4) supporting policymakers and legislators to ensure a strong regulatory environment and standards. Active engagement with the issuers is used as a tool to drive progress and influence positive change and is conducted independently and in collaboration with industry peers and broader stakeholders. Engagement activities normally focus on specific material ESG issues and involve formulating an engagement strategy with regard to such issues with the aim to track and review the progress of the issuers during this process. Regular reporting on the outcomes of active engagement can be made available on request or can be found at: www.lgim.com.

    Governance practices

    The ways in which we ensure that investee companies follow good governance practices are set out below.

    Setting expectations

    A number of policies and processes guide the engagement activities, set out the approach to investment stewardship, and outline the expectations of investee companies. The Global Corporate Governance and Responsible Investment Principles set out the approach and expectations with respect to key topics that are essential for an efficient governance framework, and for building a sustainable business model. We expect all companies on a global scale to closely align with our principles which set out the fundamentals of corporate governance. We also take into account market specificities and take a tailored approach to voting on some topics in various markets. Further related policies can be found on the Investment Stewardship section of the LGIM website.

    Active engagement

    Active engagement with the companies is used as a tool to drive progress and influence positive change and is conducted independently and in collaboration with industry peers and broader stakeholders. Engagement activities normally focus on specific material ESG issues and involve formulating an engagement strategy with regard to such issues with the aim to track and review the progress of the issuers during this process.

    Voting

    LGIM apply a common global strategy with respect to the use of voting rights, and setting expectations of investee companies with regards to planning, management and disclosure of sustainability issues. These principles impact on voting decisions, and for certain themes such as climate, gender and racial diversity there are structured voting and engagement processes in place.

    Supporting policymakers and legislators

    LGIM's Investment Stewardship team actively engages with policy makers and legislators to ensure there is strong regulation and standards in regards to governance practices.

    Investment Manager

    GO ETF Solutions LLP is the investment manager for this ETF and is responsible for its day-to-day investment management decisions. The team is highly experienced with respect to all aspects relating to the management of an ETF portfolio, including collateral management, OTC swap trading, adherence to UCITS regulations and counterparty exposure and monitoring.

    Literature

    Prices

    Name
    USD Acc
    Currency
    USD
    NAV
    19.03
    Price time
    16:00 EST (NY)

    Further details

    Charges and tax

    TER
    0.49%
    ISA eligible
    Yes
    SIPP eligible
    Yes
    UK Fund Reporting Status
    Yes

    Management / administration

    Issuer
    Legal & General UCITS ETF Plc
    Depositary and Trustee
    The Bank of New York Mellon SA/NV, Dublin Branch
    Securities regulator
    Central Bank of Ireland

    Country registration

    This share class is registered for sale in the following countries:

    Listings

    Details
    Codes
    ExchangeCurrencyTickerListing dateISINBloomberg codeReuters codeTrading hours (local)
    London Stock ExchangeGBPDOCG02/07/2019IE00BK5BC677DOCG LNDOCG.L08:00 - 16:30
    London Stock ExchangeUSDDOCT02/07/2019IE00BK5BC677DOCT LNDOCT.L08:00 - 16:30
    Borsa ItalianaEURDOCT10/09/2019IE00BK5BC677DOCT IMLGDOCT.MI09:00 - 17:30
    Deutsche BörseEURXMLH10/09/2019IE00BK5BC677XMLH GYDOCT.DE09:00 - 17:30
    SIX Swiss ExchangeCHFDOCT05/06/2020IE00BK5BC677DOCT SWDOCT.S09:00 - 17:30

    Key risks

    The value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested.

    Past performance is not a guide to the future.

    For more information, please refer to the key investor information document.

    Important information

    In the United Kingdom and outside the European Economic Area, it is issued by Legal & General Investment Management Limited, authorised and regulated by the Financial Conduct Authority, No. 119272. Registered in England and Wales No. 02091894 with registered office at One Coleman Street, London, EC2R 5AA.

    In the European Economic Area, it is issued by LGIM Managers (Europe) Limited, authorised by the Central Bank of Ireland as a UCITS management company (pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (S.I. No. 352 of 2011), as amended) and as an alternative investment fund manager with “top up” permissions which enable the firm to carry out certain additional MiFID investment services (pursuant to the European Union (Alternative Investment Fund Managers) Regulations 2013 (S.I. No. 257 of 2013), as amended). Registered in Ireland with the Companies Registration Office (No. 609677). Registered Office: 70 Sir John Rogerson’s Quay, Dublin, 2, Ireland. Regulated by the Central Bank of Ireland (No. C173733).

    LGIM Managers (Europe) Limited operates a branch network in the European Economic Area, which is subject to supervision by the Central Bank of Ireland. In Italy, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Commissione Nazionale per le società e la Borsa (“CONSOB”) and is registered with Banca d’Italia (no. 23978.0) with registered office at Via Uberto Visconti di Modrone, 15, 20122 Milan, (Companies’ Register no. MI - 2557936). In Germany, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the German Federal Financial Supervisory Authority (“BaFin”). In the Netherlands, the branch office of LGIM Managers (Europe) Limited is subject to limited supervision by the Dutch Authority for the Financial Markets (“AFM“) and it is included in the register held by the AFM and registered with the trade register of the Chamber of Commerce under number 74481231. Details about the full extent of our relevant authorisations and permissions are available from us upon request.

    We are a member of the Irish Funds Association.

    All features described on this website are those current at the time of publication and may be changed in the future. Nothing on this website should be construed as advice and it is therefore not a recommendation to buy or sell securities. If in doubt about the suitability of this product, you should seek professional advice. Copies of the prospectus, key investor information document, annual and semi-annual reports & accounts are available free of charge on request or at www.lgimetf.com.

    This website is only directed at investors resident in jurisdictions where our funds are registered for sale. It is not an offer or invitation to persons outside of those jurisdictions. We reserve the right to reject any applications from outside of such jurisdictions.

    Source and third party data

    Source: Unless otherwise indicated all data contained on this website is sourced from Legal & General Investment Management Limited.

    Where this document contains third party data ('Third Party Data’), we cannot guarantee the accuracy, completeness or reliability of such Third Party Data and accept no responsibility or liability whatsoever in respect of such Third Party Data

    Index disclaimer

    The L&G Healthcare Breakthrough UCITS ETF (the “ETF”) is not sponsored, promoted, sold or supported in any other manner by ROBO Global LLC or Solactive AG (the “Index Parties”), nor do the Index Parties offer any express or implicit guarantee or assurance either with regard to the results of using the ROBO Global® Healthcare Technology and Innovation Index (the “Index”) and/or Index trademark or the Index price at any time or in any other respect. The Index is calculated and published by Solactive AG. The Index Parties use their best efforts to ensure that the Index is calculated correctly. Irrespective of their obligations towards the Company, the Index Parties have no obligation to point out errors in the Index to third parties including but not limited to investors and/or financial intermediaries of the ETF. Neither publication of the Index by Solactive AG nor the licensing of the Index or Index trademark by ROBO Global LLC for the purpose of use in connection with the ETF constitutes a recommendation by the Index Parties to invest capital in the ETF nor does it in any way represent an assurance or opinion of the Index Parties with regard to any investment in the ETF.